Compare Five9 Inc (FIVN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Inovio Pharmaceuticals Inc — how do they compare? Five9 Inc trades at $36.22 (market cap $2.63B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Five9 Inc is far larger — about 23.4× Inovio Pharmaceuticals Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FIVN | INO | |
|---|---|---|
Market Cap | $2.63B | $112.19M |
Volume | 1,864,393 | 3,201,278 |
Sector | Technology | Health |
52-Week High | $38.65 | $2.65 |
52-Week Low | $13.61 | $0.66 |
Typical Hold Time | 72 Days | 43 Days |
Enterprise Value | $2.78B | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $36.4, up 7.76% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. Revenue growth is accelerating, reaching $1.15B in 2025, while net income turned positive at $39.42M. The stock is near its 52-week high, supported by strong AI-driven subscription growth and leadership in the contact center-as-a-service market.
Outlook remains positive given robust AI revenue growth and raised guidance, but risks include high valuation multiples and insider selling. Analyst consensus is bullish with a $34 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further upside.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
